517
Views
18
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores

, , , &
Pages 340-347 | Received 01 Mar 2017, Accepted 04 Jun 2017, Published online: 20 Jun 2017
 

Abstract

We evaluated the usefulness of interim 18F-FDG PET/CT for risk stratification using different cutoff values of the Deauville 5-point scale (5-DS) in DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). One hundred and fifty patients underwent interim (I-) and end of treatment (EOT-) PET/CT scans. Applying the conventional 5-DS cutoff value of scores 4 to 5 at interim, there was no significant difference in progression free survival (PFS) between I-PET negative and I-PET positive patients. In comparison, PFS was inferior in patients with a score of 5 on I-PET scan compared with those with a score in between 1 to 4 (28.6% vs. 78.7%, p < .0001), and positive predictive value (71.4%) was improved compared to that obtained using cutoff value of scores 4 to 5 (34.9%). Our study shows that a cutoff score of 5 at interim has an alternative clinical implication for identifying patients at a significant risk.

Acknowledgements

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2016R1D1A1A02937028).

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1339877.

Additional information

Funding

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2016R1D1A1A02937028).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.